AbbVie Inc. (ABBV)
| Previous close | 115.08 |
| Open | 115.13 |
| Bid | 114.94 x 900 |
| Ask | 114.96 x 800 |
| Day's range | 114.46 - 115.55 |
| 52-week range | 79.11 - 119.15 |
| Volume | 2,368,536 |
| Avg. volume | 6,241,295 |
| Market cap | 203.049B |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | 30.99 |
| EPS (TTM) | 3.71 |
| Earnings date | 28 Oct 2021 - 01 Nov 2021 |
| Forward dividend & yield | 5.20 (4.47%) |
| Ex-dividend date | 14 July 2021 |
| 1y target est | 124.08 |
- PR Newswire
JAMA Dermatology Publishes Data Showing RINVOQ® (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) for Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis
AbbVie (NYSE: ABBV) today announced that JAMA Dermatology has published 24-week results from the Phase 3b Heads Up study evaluating the efficacy and safety of RINVOQ® (upadacitinib, 30 mg, once daily) versus DUPIXENT® (dupilumab, 300 mg, every other week) – both as monotherapy treatments – in adults with moderate to severe atopic dermatitis who were candidates for systemic therapy.
- Motley Fool
3 Underrated Warren Buffett Stocks That Are Smart Buys Right Now
You might think that any stock handpicked by Warren Buffett and his top investment managers would be held in high regard by most investors. Several stocks in Berkshire Hathaway's (NYSE: BRK.A) (NYSE: BRK.B) portfolio are either beaten down, have bargain valuations, or both. Here are three underrated Buffett stocks that are smart buys right now.
- Motley Fool
AbbVie (ABBV) Q2 2021 Earnings Call Transcript
ABBV earnings call for the period ending June 30, 2021.
